{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:40:30Z","timestamp":1786534830374,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euf.2026.06.026","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:16:43Z","timestamp":1786533403000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Perioperative Circulating Tumor DNA in Pure Urothelial Carcinoma and Histological Subtypes of Bladder Cancer"],"prefix":"10.1016","author":[{"given":"Pierre-Etienne","family":"Gabriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1935-483X","authenticated-orcid":false,"given":"Alec","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Eraky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Ben-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.06.026_b0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.06.026_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.06.026_b0015","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.06.026_b0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/JU.0000000000002242","article-title":"Management trends and outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder: evolution of the University of Southern California experience over 3,347 cases","volume":"207","author":"Mitra","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.06.026_b0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bju.15984","article-title":"Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy","volume":"132","author":"Claps","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.06.026_b0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.06.026_b0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.euf.2017.06.013","article-title":"The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy","volume":"5","author":"Li","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.06.026_b0040","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.3390\/jcm13154349","article-title":"The prognostic significance of histological subtypes in patients with muscle-invasive bladder cancer: an overview of the current literature","volume":"13","author":"Claps","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.euf.2026.06.026_b0045","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and clinical significance of histological variants of bladder cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2026.06.026_b0050","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.31952","article-title":"Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: does histologic subtype matter?","volume":"125","author":"Berg","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2026.06.026_b0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urolonc.2007.07.010","article-title":"The impact of variant histology on the outcome of bladder cancer treated with curative intent","volume":"27","author":"Black","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2026.06.026_b0060","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/JU.0000000000003836","article-title":"Impact of divergent differentiation and\/or histological subtype of urothelial carcinoma on patient outcomes in the GETUG-AFU V05 VESPER trial","volume":"211","author":"Allory","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.06.026_b0065","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.euo.2024.03.002","article-title":"Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy","volume":"7","author":"Ben-David","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.06.026_b0070","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bju.16556","article-title":"Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes","volume":"135","author":"Ben-David","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.06.026_b0075","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.euo.2024.07.001","article-title":"Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer","volume":"8","author":"Sfakianos","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.06.026_b0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euo.2023.05.012","article-title":"Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: a systematic review","volume":"7","author":"Crupi","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.06.026_b0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11912-019-0772-8","article-title":"Clinical and genomic considerations for variant histology in bladder cancer","volume":"21","author":"Matulay","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.euf.2026.06.026_b0090","doi-asserted-by":"crossref","first-page":"56398","DOI":"10.18632\/oncotarget.17657","article-title":"Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study","volume":"8","author":"Soave","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2026.06.026_b0095","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male Genital organs-part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.06.026_b0100","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2026.06.026_b0105","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1097\/JS9.0000000000001372","article-title":"Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis","volume":"110","author":"Liu","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.euf.2026.06.026_b0110","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/MOU.0000000000001221","article-title":"Tumor-informed circulating tumor DNA in urothelial carcinoma: a promising novel biomarker","volume":"34","author":"Ben-David","year":"2024","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2026.06.026_b0115","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.06.026_b0120","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.06.026_b0125","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","article-title":"High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial","volume":"29","author":"van Dorp","year":"2023","journal-title":"Nat Med"},{"issue":"Suppl 6","key":"10.1016\/j.euf.2026.06.026_b0130","article-title":"A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA)","volume":"40","author":"Powles","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.06.026_b0135","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2026.06.026_b0140","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.06.026_b0145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","article-title":"Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants","volume":"75","author":"Warrick","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.06.026_b0150","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.euf.2022.04.017","article-title":"Circulating tumour DNA is a strong predictor of outcomes in patients treated with systemic therapy for urothelial carcinoma","volume":"8","author":"Laukhtina","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.06.026_b0155","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:16:48Z","timestamp":1786533408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926001227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S2405456926001227"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.06.026","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of Perioperative Circulating Tumor DNA in Pure Urothelial Carcinoma and Histological Subtypes of Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}